semaglutide and iron GLP-1 SEMA Peptide 10MG GLP-1 Medications and Iron Absorption:

Individuals with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use Semaglutide 14mg tablets

There are some risks associated with compounded tirzepatide (as well as similar drugs like compounded semaglutide), such as: Dosing errors resulting from incorrectly measuring the dose, which can lead to serious side effects from taking too much medicine (With Mounjaro, the dose is loaded into the prefilled pen, so it is unlikely you will inject an incorrect dose.) Ingredients, such as retatrutide, that are labeled for research purposes or not for human consumption and have been found in compounded products that are provided to patients Contaminated and non-sterile products, which can be dangerous Counterfeit drugs, that may contain the wrong drug, too much or too little of the drug, or no drug at allalong with illegal sales that do not require a prescription In addition to these risks, remember that compounded tirzepatide products have not been tested or FDA approved, so it is not known if the product you receive is safe, effective, and of high quality

Quality of life enhancements, including improved mobility, self-confidence, and ability to participate in desired activities, constitute important treatment outcomes

According to the STEP 1 trial, the average weight loss at 68 weeks was 14.9% of body weight [1] on the 2.4mg maintenance dose